DYDROGESTERONE ( DrugBank: Dydrogesterone )


1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-005129-10-FI
(EUCTR)
27/01/201512/12/2014Multiple Sclerosis, menopause and hormone replacement therapyMultiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis Multiple sclerosis
MedDRA version: 17.1;Level: LLT;Classification code 10064137;Term: Progression of multiple sclerosis;System Organ Class: 100000004852
MedDRA version: 17.1;Classification code 10070425;Term: Multiple sclerosis exacerbation;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Femoston 2/10
Product Name: Femoston 2/10
INN or Proposed INN: ESTRADIOL HEMIHYDRATE
INN or Proposed INN: DYDROGESTERONE
Trade Name: Femoston 1/10
Product Name: Femoston 1/10
INN or Proposed INN: ESTRADIOL HEMIHYDRATE
INN or Proposed INN: DYDROGESTERONE
Irina ElovaaraNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: no
Finland